Novo Nordisk Tops Quarterly Views, Tempers Full-Year Outlook
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
FDA to Speed up AI Rollout to Accelerate Drug Reviews
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
Research Alert: CFRA Keeps Hold Opinion On Adss Of Novo Nordisk
UBS Group: Novo-Nordisk A/S (NVO.US) is under short-term pressure but this does not change its long-term value, maintaining a "Buy" rating.
UBS Group believes that Novo-Nordisk A/S's leading position in the treatment of diabetes and obesity, along with its strong R&D pipeline, gives it long-term investment value.
Novo Nordisk AS (NVO) Q1 2025 Earnings Call Highlights: Robust Growth Amid Challenges
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Health Care Up After Novo Nordisk Earnings -- Health Care Roundup
Super Micro, AMD, Marvell, Palantir, Disney, Uber, Novo, EA: Biggest Movers
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Novo Nordisk Shares Are Rising After the Company Cut Its Outlook. It's Been That Kind of Year.
Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took It By Surprise -- Barrons.com
Novo Nordisk Drops Gender Representation Goals in US
Sector Update: Health Care Stocks Advance Pre-Bell Wednesday
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Today's Pre-Market Movers and Top Ratings | DIS, NVO, UBER and More
6-K: Financial Report for the Period 1 January 2025 to 31 March 2025
Express News | Watching Novo Nordisk: Hearing Novo Nordisk Head Of U.S. Operations Says We Fully Expect The FDA To Enforce The Ban On Drug Compounding; We Will Continue To Fight Against Unlawful Compounding